Literature DB >> 16048263

Peritoneal dialysis prescription for diabetic patients.

Qiang Yao1, Bengt Lindholm, Olof Heimbürger.   

Abstract

The number of end-stage renal disease (ESRD) patients with diabetes mellitus has increased dramatically during the past few years and, in many countries, diabetes has become the most important cause of ESRD in patients admitted to dialysis. Furthermore, compared to nondiabetic patients, diabetic patients continue to suffer from more frequent and severe comorbidity and complications, including cardiovascular disease, poor fluid balance, worse quality of life, as well as high morbidity and mortality after initiation of dialysis. These systemic problems in diabetic patients should influence the dialysis prescription. In addition, the structure and transport properties of the peritoneal membrane may deteriorate as a consequence of diabetes. Thus, both the systemic and the peritoneal consequences of diabetes influence the dialysis prescription in diabetic patients. In this brief review, we discuss the care of diabetic ESRD patients on peritoneal dialysis--which, compared with hemodialysis, has both advantages and disadvantages in this group of patients--focusing on the special needs for intense and integrated care involving individualized dialysis prescription as well as care of diabetic complications and comorbidity in this diseased patient group.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16048263

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  2 in total

1.  Peritoneal dialysis in diabetics: there is room for more.

Authors:  P Cotovio; A Rocha; A Rodrigues
Journal:  Int J Nephrol       Date:  2011-10-16

2.  Renal Replacement Therapy: Purifying Efficiency of Automated Peritoneal Dialysis in Diabetic versus Non-Diabetic Patients.

Authors:  Nicanor Vega-Diaz; Fayna Gonzalez-Cabrera; Silvia Marrero-Robayna; Raquel Santana-Estupiñan; Roberto Gallego-Samper; Fernando Henriquez-Palop; Patricia Perez-Borges; José Carlos Rodriguez-Perez
Journal:  J Clin Med       Date:  2015-07-22       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.